Sign in

NCT03269422CompletedPhase 1

Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)

A Phase I Feasibility Study of Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR Image-Guided, Intensity-Modulated Radiotherapy

Source: ClinicalTrials.gov · Last updated 31 Jul 2026

Brief summary (registry, in English)

The purpose of the study is to find out the feasibility and effects of ultra-hypofractionated radiotherapy to the prostate and dominant lesion as definitive treatment for intermediate risk prostrate cancer.

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
35 (actual)
First submitted
29 Aug 2017
Start date
28 Aug 2017
Primary completion date
29 Jul 2026
Lead sponsor
Memorial Sloan Kettering Cancer Center
NCT number
NCT03269422

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 35
  • From 28 Aug 2017 to the primary completion date, 29 Jul 2026
  • 7 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Prior androgen deprivation therapy for prostate cancer
  • Metallic hip implant, metallic implant or device in the pelvis that might distort the local magnetic field and compromise quality of MP-MRI.
  • Contra-indications to receiving gadolinium contrast
  • Prior history of transurethral resection of the prostate
  • Prior history of chronic prostatitis
  • Prior history of urethral stricture
  • Prior history of pelvic irradiation

Other illness

  • Evidence of metastatic disease on bone scan or MRI/CT
  • MRI ineligibility due to the presence of a cardiac pacemaker, defibrillator or other implanted metallic or electronic device which is considered MR unsafe, severe claustrophobia or inability to lie flat for the duration of the study, etc.
  • Pelvic MRI or CT (MRI preferred) evidence of radiographic T3, T4 or N1 disease.
  • History of inflammatory bowel disease

Lab values

  • Abnormal complete blood count. Any of the following
    • Platelet count less than 75,000/ml
    • Hb level less than 10 gm/dl
    • WBC less than 3.5/ml
  • Abnormal renal function tests (creatinine \> 1.5)

Other

  • Lateral pelvic separation greater than 50 cm and/or anterior-posterior separation greater than 35 cm which are incompatible with MRCAT reconstruction
  • KPS \< 80
  • Unable to give informed consent
  • Unable to complete quality of life questionnaires

Who the study is looking for

  • Intermediate risk prostate cancer patients will be eligible for this study. Risk groups will be assigned as per NCCN guidelines. Intermediate risk patients will be defined as:
    • PSA 10-20 ng/ml or
    • Gleason score = 7 or
    • Clinical stage T2b/T2c
  • Additionally, patients will be required to meet the following criteria:
    • Age \>18
    • KPS \> 80
    • Prostate size \< 60cc
    • Presence of a prostatic lesion with maximum dimension of \>/= 0.5cm and no more than two additional disease foci, each with a maximum dimension less than that of the dominant lesion.
    • International Prostrate Symptom Score \< 15
    • Subjects must fill out the standard MRI screening form and satisfy all MRI screening criteria

Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (7)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Memorial Sloan Kettering Basking Ridge (Consent only and follow up)
Coordinator of this site? Confirm its status
Basking RidgeUnited StatesUnknown status
Memorial Sloan Kettering Commack
Coordinator of this site? Confirm its status
CommackUnited StatesUnknown status
Memorial Sloan Kettering Westchester
Coordinator of this site? Confirm its status
East White PlainsUnited StatesUnknown status
Memorial Sloan Kettering Monmouth
Coordinator of this site? Confirm its status
MiddletownUnited StatesUnknown status
Memorial Sloan Kettering Bergen
Coordinator of this site? Confirm its status
MontvaleUnited StatesUnknown status
Memorial Sloan-Kettering Cancer Center
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
Memorial Sloan Kettering Nassau (Consent and Follow up)
Coordinator of this site? Confirm its status
UniondaleUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.